Generation Bio CO 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Generation Bio Co. reported a net loss of $5.5 million for Q3 2025, announced a 90% workforce reduction, and is exploring strategic alternatives including potential dissolution.
Generation Bio Co. announced a significant strategic restructuring, including a 90% workforce reduction and the exploration of strategic alternatives, while reporting a reduced net loss for the first half of 2025.
10-Q: Generation Bio Co. Reports First Quarter 2025 Financial Results, Collaboration Revenue Increases
Generation Bio Co. reports increased collaboration revenue and provides updates on its T cell-driven autoimmune disease program in its Q1 2025 financial results.
Generation Bio reported a net loss of $15.3 million for the third quarter of 2024, with collaboration revenue increasing due to its partnership with Moderna.
Generation Bio's Q2 2024 results reflect increased collaboration revenue, reduced operating expenses due to a strategic reorganization, and a significant loss from lease termination.
Generation Bio reported a net loss of $74.5 million for the first quarter of 2024, impacted by a significant loss on lease termination.